Free Trial
NYSE:CATX

Perspective Therapeutics (CATX) Stock Price, News & Analysis

Perspective Therapeutics logo
$2.85 +0.01 (+0.35%)
(As of 12/20/2024 05:16 PM ET)

About Perspective Therapeutics Stock (NYSE:CATX)

Key Stats

Today's Range
$2.80
$2.96
50-Day Range
$2.84
$13.00
52-Week Range
$2.70
$19.05
Volume
2.86 million shs
Average Volume
883,322 shs
Market Capitalization
$192.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.14
Consensus Rating
Moderate Buy

Company Overview

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Perspective Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
68th Percentile Overall Score

CATX MarketRank™: 

Perspective Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 353rd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Perspective Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Perspective Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Perspective Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.88) to ($1.22) per share.

  • Price to Book Value per Share Ratio

    Perspective Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for CATX.
  • Dividend Yield

    Perspective Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Perspective Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CATX.
  • News Sentiment

    Perspective Therapeutics has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Perspective Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    12 people have searched for CATX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Perspective Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $256,789.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 3.52% of the stock of Perspective Therapeutics is held by insiders.

  • Percentage Held by Institutions

    54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Perspective Therapeutics' insider trading history.
Receive CATX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CATX Stock News Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Perspective Therapeutics: Definitely Not Looking Overvalued Now
Perspective Therapeutics management to meet with Truist
See More Headlines

CATX Stock Analysis - Frequently Asked Questions

Perspective Therapeutics' stock was trading at $11.90 at the start of the year. Since then, CATX stock has decreased by 76.1% and is now trading at $2.85.
View the best growth stocks for 2024 here
.

Perspective Therapeutics, Inc. (NYSE:CATX) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.21). The firm had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative trailing twelve-month return on equity of 27.40% and a negative net margin of 4,096.66%.

Perspective Therapeutics's stock reverse split on Monday, June 17th 2024. The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Top institutional shareholders of Perspective Therapeutics include FMR LLC (8.16%), Janus Henderson Group PLC (7.10%), State Street Corp (3.24%) and Nicholson Wealth Management Group LLC (2.57%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Robert F Williamson III, Lori A Woods, Markus Puhlmann, Jonathan Robert Hunt, Johan M Spoor and Heidi Henson.
View institutional ownership trends
.

Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Perspective Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Chevron (CVX).

Company Calendar

Last Earnings
11/12/2024
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Employees
116
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.14
High Stock Price Target
$21.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+431.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-46,510,000.00
Net Margins
-4,096.66%
Pretax Margin
-3,780.02%

Debt

Sales & Book Value

Annual Sales
$1.43 million
Book Value
$2.67 per share

Miscellaneous

Free Float
65,209,000
Market Cap
$192.63 million
Optionable
Optionable
Beta
1.13
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NYSE:CATX) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners